Study of Sotorasib Combined With Chemotherapy for Second Line Treatment of Pancreas Cancer

Study of Sotorasib Combined With Chemotherapy for Second Line Treatment of Pancreas Cancer
Conditions:   Pancreatic Cancer;   Unresectable Pancreatic Cancer;   Metastatic Pancreatic Cancer;   KRAS P.G12C
Interventions:   Drug: Sotorasib;   Drug: Liposomal Irinotecan (nal-IRI);   Drug: 5 Fluorouracil (5FU);   Drug: Leucovorin (LV);   Drug: Gemcitabine (GEM);   Drug: Nab paclitaxel
Sponsors:   Devalingam Mahalingam;   Amgen
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

September 27, 2022Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
Comments